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Objective: Three single nucleotide polymorphisms (SNPs), 1082, 819 and 592, located on
the promoter region of IL10 gene have been associated with high in vitro IL-10 production
and autoimmune diseases. We aim to investigate whether polymorphisms in the IL10 gene
would influence dental implant loss.
Methods: We evaluated a total of 277 unrelated patients, including 185 individuals present-
ing at least one osseointegrated implant in function for six months or more and with no
implant failure, and 92 individuals presenting at least one implant loss. DNA was extracted
from buccal mucosa cells and SNPs were genotyped using TaqMan1 probes-based assays.
Results: Multiple logistic regression showed association between dental implant failure with
819(C/T) genotype (OR = 3.27; 95% CI = 1.02–10.46; p = 0.0334). However, considering the
statistical significance level a = 0.004 (adjusted by Bonferroni correction of multiple com-
parisons), these results lost their significance. No association of dental implant loss with
genotypes and alleles of the 1082 and 592 SNPs, as well as IL10 haplotypes in genotype/
allele forms were found ( p = 0.9400; p = 0.8861).
Conclusions: Neither the IL10 gene polymorphisms, nor haplotypes or other covariates were
associated with susceptibility to dental implant failure in the studied population.
# 2012 Elsevier Ltd. 
Available online at www.sciencedirect.com
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Open access under the Elsevier OA license.1. Introduction
Osseointegrated dental implants have been considered the
most aesthetical and functional alternative to missing teeth.1
The success rate in patients treated with dental implants is
high for all implant systems,2 varying according to prospective
and retrospective studies from 85 to 100%.3–6 However, in spite
of these high success rates of treatments with dental implants,* Corresponding author at: UNESP – Univ Estadual Paulista, Araraquara S
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Open access under the Elsevier OA license.failures can occur generating the concept that dental implant
osseointegration failure is a complex and multifactorial trait.7–
9 Therefore, this issue has been investigated in many studies
by different research groups.7,10–13 The process of dental
implant osseointegration failure can be divided into early,
when osseointegration fails occur, and late, when the
achieved osseointegration is lost after a period of function.14
Early failures have been related to surgical trauma,15 contam-
ination during the surgical procedure16 and bone quantity andchool of Dentistry, Department of Morphology, Rua Humaita´, 1680,
fax: +55 16 3301 6488.
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and occlusal overload.19 In addition, biological and social
aspects influence implant failure, such as smoking20 and
medical conditions.21
In spite of adequate clinical conditions, dental implants
osseointegration failures occur. A very plausible cause for this
problem is related with the host immune response. An
abnormal immune-inflammatory response involving different
cell types such as macrophages, polymorphonuclear neutro-
phils, T and B lymphocytes, endothelial cells, fibroblasts,
keratinocytes, osteoclasts and osteoblasts can destroy the
periimplant and periodontal tissues.22 Moreover, an intense
inflammatory process, mediated by cytokines, could impair
osseointegration and lead to implant loss.11 High levels of IL-
1B were found in diseased implant sites when compared with
healthy sites.23 However, levels of other cytokines, such as
tumour necrosis factor alpha (TNF-a), have no correlation with
the disease around implants.24 Alternatively, the concentra-
tion of platelet-activating factor (PAF), a phospolipid mediator
produced by inflammatory and endothelial cells and capable
of activating osteoclastic resorption, was increased in gingival
tissue around failed dental implants, suggesting that an
enhanced local production of PAF might be associated with
implant failures.25
The interleukin 10 (IL-10) is an anti-inflammatory cytokine,
produced by T-helper 2 cells (Th2), macrophages and B cells,
which inhibits synthesis of pro-inflammatory cytokines such
as IL-1, IL-2, IL-6, IL-8, TNF-a and IFN-g (interferon gamma). On
the other hand, IL10 acts as a B cell stimulator, enhancing B
cell proliferation and differentiation.26 These facts suggest
that IL10 can play important roles in the regulation of cellular
and humoral immune responses.27
The expression levels of the IL-10 may be modulated by
genetic polymorphisms in regulatory regions of the gene,
mainly the promoter region localized upstream of the start
codon of the gene.28 Polymorphisms in promoter sequences of
genes result in abnormal transcriptional regulation and
thereby influence the development of the disease severity.29
The gene encoding IL-10 is located on chromosome 1q31-
32.30 IL10 promoter region is highly polymorphic and there are
three single base pair substitutions in the IL10 gene promoter
at positions 1082 (rs1800896), 819 (rs1800871) and 592
(rs1800872) from the transcriptional start site. The IL10 gene
polymorphism at position 1082 is a G to A substitution and
lies within a putative Ets (E-twenty six) transcription factor
binding site.31 This polymorphism was demonstrated as
functional, since the presence of the A allele influenced lower
levels of the IL-10 production in vitro.32 The 819 polymor-
phism is a C to T substitution and may affect an oestrogen
receptor element.33 The allele T of this polymorphism was
recently associated with Behcet’s disease susceptibility loci in
a Japanese population by a genome wide association study
(GWAS).34 The 592 polymorphism is a C to A substitution and
lies within a region with a negative regulatory function.31
These single nucleotide polymorphisms (SNPs) were associat-
ed with allergies, asthma,29 systemic lupus erythematosus33
and chronic periodontitis.35–37 The functionality of the
haplotypes was demonstrated, since the ATA/ATA genotype
was associated with lower IL-10 production following lipopo-
lyssacharide (LPS) stimulation than other genotypes.38Given the important role of the IL-10 in the host
inflammatory response and the previously demonstrated
association of the 1082, 819 and 592 SNPs in the IL10
gene with other complex diseases, it was hypothesized in this
study whether those SNPs and the haplotypes formed by them
could influence the occurrence of dental implant failure.
2. Materials and methods
2.1. Subject selection
A total of 3578 patient records from the Latin-American Dental
Research Institute (ILAPEO) of Curitiba/BR were analysed in
this study. All patients were implant treated (NEODENTTM
Implante Osteointegra´vel) between 1996 and 2006, and out of
those subjects treated, 126 patients (3.5%) presented at least
one implant loss (early failure). From those 126 individuals
that presented implant loss, 92 were evaluated (34 subjects
were not evaluated because of death or address change). Thus,
the dental implant failure group (DIF) was composed by 92
individuals presenting at least one implant loss. The control
group was matched by gender, age and smoking, and was
composed by 185 patients treated with osseointegrated
implants, with at least one implant in function for more than
6 months and without any loss (Table 1).
The sample was composed of 277 unrelated, both gender,
mean age 53.79 (11.3) years old individuals. The study sample
was from the southern region of Brazil and the subjects
answered an anamnesis as well as had their socioeconomic
profile assessed according to the Brazilian Economical
Classification Criteria.39
Subjects in good general health could not have any of the
following exclusion criteria: HIV infection, current pregnancy
or lactation, orthodontic appliances, present necrotizing
ulcerative gingivitis and periodontitis, and history of aggres-
sive periodontitis.
The patients signed a consent form within a protocol
approved by an Institutional Review Board, after being advised
of the study nature (approved by the Ethical Committee in
Research at PUCPR, protocol 323).
2.2. DNA collection and purification
From all subjects, epithelial buccal cells were sampled
according to the procedure described in Trevilatto and Line.40
DNA was extracted from epithelial buccal cells with ammoni-
um acetate 10 M and EDTA 1 mM.41
2.3. Analysis of genetic polymorphisms
The analyses of genetic polymorphisms were performed using
real-time polymerase chain reaction (RT-PCR) with TaqMan
SNP Genotyping Assays (Applied Biosystems, Foster City, CA,
USA). The SNPs in the IL10 gene 1082(G/A) (rs1800896),
819(C/T) (rs1800871) and 592(C/A) (rs1800872) were geno-
typed using predesigned TaqManTM genotyping assays (ABI ID.
C_1747360_10, C_1747362_10 and C_1747363_10, respectively).
For all TaqMan assays, DNA amplification was carried out in
12.5 ml volume containing 20 ng DNA, 2.4 mM primers and
Table 1 – Features of the studied population.
Feature Controls Dental implant failure Total p
Total of individuals n = 185 (%) n = 92 (%) n = 277 (%)
Mean age (SD) 53.1 (11.5) 55.13 (10.8) 53.79 (11.3) 0.5000
Gender
Female 121 (65.4) 55 (59.8) 176 (63.6) 0.4335
Male 64 (34.5) 37 (40.2) 101 (36.4)
Smoking habits
Smokers 44 (23.6) 17 (18.5) 61 (21.9) 0.0001
Nonsmokers 141 (76.4) 75 (81.5) 216 (78.1)
Dental mobilitya
Yes 19 (12.6) 15 (17.7) 34 (14.4) 0.3840
No 132 (87.4) 70 (82.3) 202 (85.6)
Rheumatoid disease
Yes 34 (18.3) 25 (27.2) 59 (21.3) 0.1265
No 151 (81.7) 67 (72.8) 218 (78.7)
Cardiovascular disease
Yes 10 (5.4) 8 (8.7) 18 (6.5) 0.4310
No 175 (94.6) 84 (91.3) 259 (93.5)
Hypertension
Yes 37 (19.9) 24 (26.0) 61 (22,1) 0.3185
No 148 (80.1) 68 (74.0) 216 (77.9)
Medical treatment
Yes 75 (40.3) 43 (46.7) 118 (42.6) 0.3933
No 110 (59.7) 49 (53.3) 159 (57.4)
NSAI
Yes 39 (20.9) 18 (19.5) 57 (20.6) 0.8917
No 146 (79.1) 74 (80.5) 220 (79.4)
SAI
Yes 2 (1.1) 0 (0.0) 2 (0.7) 0.8045
No 183 (98.9) 92 (100) 275 (99.3)
Clinical appointments
0–2 51 (27.4) 28 (30.4) 79 (28.5)
3–5 70 (38.2) 38 (41.3) 108 (39) 0.2156
6–11 61 (32.8) 25 (27.1) 86 (31)
12–24 3 (1.6) 1 (1.2) 4 (1.5)
Bold indicates statistical sifnificant values
a Edentulous patients: control = 34 (18.3%) and dental implant failure = 7 (7.6%). NSAI: Non Steroidal Antiinflammatory; SAI: Steroidal
Antiinflammatory.
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were made in a 7500 Real Time PCR System (Applied
Biosystems, Foster City, CA, USA). Subsequently, end-point
fluorescence was determined using 7500 System Sequence
Detection Software (Applied Biosystems, Foster City, CA, USA).
2.4. Statistical analysis
We used the chi-squared test in order to verify differences
between cases and controls for the following features: gender,
smoking habits, dental mobility, rheumatoid or cardiovascu-
lar disease, presence of hypertension, medical treatment,
current medication of anti-inflammatory non-steroidal drug
(AINES) or anti-inflammatory steroidal drug (AIES) and dental
clinical appointments. In addition, mean age difference
between groups was evaluated using t-test. Both analyses
were performed by BioEstat statistical package version 5.0
(UFPA, MCT, CNPq, Bele´m, PA, Brazil).
Minor allele frequency (MAF), Hardy–Weinberg disequilibri-
um and linkage disequilibrium (LD) were estimated using
HAPLOVIEW software.42 We analysed genetic association
between polymorphisms and dental implant failure using
multiple logistic regression, including the features cited aboveas covariates. This analysis was performed using the R
statistical package (R Development Core Team, Vienna,
Austria).
To verify statistical power of our sample, we used G*POWER
software,43 with the following parameters: logistic regression
test; two tail analysis, odds ratio (OR) = 2.7; and statistical
significance level a = 0.004, adjusted by Bonferroni correction
of multiple comparisons. This OR = 2.7 was the mean value
obtained from our initial estimation, OR = 3.04 and OR = 2.41 of
the 819 and 592 SNPs, respectively, for IL10 gene using a
similar population.37
Haplotypes were evaluated by expectation-maximization
(EM) algorithm within ARLEQUIN software.44 Differences in
haplotype distribution between groups were assessed using
Markov Chain Monte Carlo (MCMC) simulation by CLUMP
software.45 Differences between groups were considered
significant when p < 0.05.
3. Results
Statistical power estimation for our sample showed 99.9% for
association detection. Excepting for smoking habits
Table 2 – Logistic regression results for the polymorphisms.
Polymorphism Control
n (%)
DIF
n (%)
OR (95% CI) p
Nominal Corrected
1082 (A/G) Total n = 358 n = 184
HW disequilibrium p = 0.4124 p = 0.5669
Allele A 220 (61.4) 113 (61.4) Reference –
G 138 (38.6) 71 (38.6) 1.05 (0.55–1.99) 0.8811 1.0000
Genotype AA 65 (36.3) 36 (39.1) Reference –
AG 90 (50.3) 41 (44.5) 0.98 (0.48–2.04) 0.9662 1.0000
GG 24 (13.4) 15 (16.4) 2.13 (0.75–6.08) 0.1450 1.0000
819 (C/T) Total n = 354 n = 172
H–W disequilibrium p = 0.8245 p = 0.7996
Allele C 240 (67.7) 112 (65.2) Reference –
T 114 (32.2) 60 (34.8) 2.38 (0.8–7.13) 0.1007 1.0000
Genotype CC 82 (46.5) 37 (43.0) Reference –
CT 76 (42.9) 38 (44.2) 3.27 (1.02–10.46) 0.0334 0.4008
TT 19 (10.6) 11 (12.8) 0.32 (0.01–13.52) 0.0420 0.5040
592 (A/C) Total n = 364 n = 184
H–W disequilibrium p = 0.8734 p = 0.4682
Allele A 251 (68.9) 122 (66.4) Reference –
C 113 (31.1) 62 (33.6) 0.54 (0.19–1.56) 0.2307 1.0000
Genotype AA 87 (47.4) 42 (45.6) Reference –
AC 77 (42.3) 38 (41.3) 0.49 (0.16–1.52) 0.1939 1.0000
CC 18 (10,3) 12 (13,1) 4.69 (0.11–206.24) 0.2750 1.0000
DIF: dental implant failure; H–W = Hardy–Weinberg; OR (95% CI): odds ratio values with the respective 95% of confidence intervals.
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features between cases and controls (Table 1). In addition,
none polymorphism showed MAF < 0.05 or Hardy–Weinberg
disequilibrium. Significant associations between the dental
implant failure and 819(C/T) genotype, rheumatoid and
cardiovascular diseases were observed by multivariate analy-
sis (Tables 2 and 3). However, considering the statistical
significance level a = 0.004 (adjusted by Bonferroni correctionTable 3 – Logistic regression results for the covariates analyse
Covariate Control
n (%)
Smoking habits Nonsmokers 141 (76.4) 
Smokers 44 (23.6) 
Dental mobility No 19 (12.6) 
Yes 132 (87.4) 
Rheumatoid disease No 34 (18.3) 
Yes 151 (81.7) 
Cardiovascular disease No 10 (5.4) 
Yes 175 (94.6) 
Hypertension No 37 (19.9) 
Yes 148 (80.1) 
Medical treatment No 75 (40.3) 
Yes 110 (59.7) 
NSAI No 39 (20.9) 
Yes 146 (79.1) 
SAI No 2 (1.1) 
Yes 183 (98.9) 
Dental clinical appointments 0–2 51 (27.4) 
3–5 70 (38.2) 
6–11 61 (32.8) 
12–24 3 (1.6) 
DIF: dental implant failure.of multiple comparisons), these results lost their significance.
The multiple logistic regression analysis demonstrated that
neither smoking habits nor other genotypes, alleles or other
variables were associated with dental implant failure, even
after adjusting for covariates (Tables 2 and 3).
Significant linkage disequilibrium was observed for all the
investigated polymorphisms (Fig. 1). The more frequent
haplotype in both groups was the GCA and the haplotypesd.
DIF
n (%)
OR (95% CI) p
Nominal Corrected
75 (81.5) Reference –
17 (18.5) 0.87 (0.42–1.78) 0.6829 1.0000
15 (17.7) Reference –
70 (82.3) 1.3 (0.57–2.97) 0.5203 1.0000
25 (27.2) Reference –
67 (72.8) 2.21 (1.01–4.84) 0.0376 0.4512
8 (8.7) Reference –
84 (91.3) 4.14 (1.01–17.05) 0.0293 0.3516
24 (26.0) Reference –
68 (74.0) 1.22 (0.57–2.63) 0.5898 1.0000
43 (46.7) Reference –
49 (53.3) 1.06 (0.55–2.04) 0.8642 1.0000
18 (19.5) Reference –
74 (80.5) 0.86 (0.41–1.79) 0.6743 1.0000
0 (0.0) Reference –
92 (100) 0.71 (0.06–8.71) 0.7606 1.0000
28 (30.4) Reference –
38 (41.3) 0.92 (0.42–2.00) 0.8199 1.0000
25 (27.1) 0.97 (0.43–2.18) 0.9315 1.0000
1 (1.2) 1.52 (0.08–27.8) 0.7342 1.0000
Fig. 1 – Linkage disequilibrium (LD) map for the SNPs
genotyped in this study. Numbers represent pairwise
percent D0-values for LD between each marker.
Table 5 – Distribution of IL10 haplotypes (arranged as genotyp
Haplotypes
1082 592 819
Control
n = 170 (%)
Dental impla
n = 86
GCA/ATC 42 (25.0) 20 (23.2) 
ACA/ACA 17 (10.0) 6 (6.9) 
ACA/GCA 37 (22.0) 16 (19.2) 
ATC/ATC 18 (10.2) 12 (13.9) 
ACC/GCA 3 (1.3) 2 (2.13) 
GCA/GCA 22 (13.2) 13 (15.1) 
ATC/ACA 27 (16.0) 15 (17.4) 
ACA/ATA 2 (1.20) 2 (2.17) 
ACA/ACC 1 (0.55) 0 (0.0)
GTA/GTA 1 (0.55) 0 (0.0)
p = 0.9400z
OR (95% CI): odds ratio values with the respective 95% of confidence int
y OR not calculated because of the presence of zero.
z p value obtained from the CLUMP program.
Table 4 – Distribution of the IL10 haplotypes in the studied gr
Haplotypes
1082 592 819
Control
n = 340 (%)
Dental impla
n = 172
GCA 126 (37.0) 64 (37
ATC 105 (30.9) 59 (34
ACA 101 (29.7) 45 (26
ACC 4 (1.1) 2 (1.
ATA 2 (0.6) 2 (1.
GTA 2 (0.6) 0 (0.
p = 0.8861z
OR (95% CI): odds ratio values with the respective 95% of confidence int
y OR not calculated because of the presence of zero.
z p value obtained from the CLUMP program.
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control and dental implant failure groups (Tables 4 and 5).
4. Discussion
Interleukin-10 has been cited as being of major significance in
the immunopathogenesis of chronic inflammatory diseases,
such as periodontal disease,46 allergies, asthma29 and system-
ic lupus erythematosus.33 IL-10 may be critical in controlling
the balance between Th1 and Th2 cells in chronic periodonti-
tis; whereby an excess of interleukin-10 may shift the balance
in favour of a Th2 response and contribute with the
progression of the disease, whereas IL-10 deficiency may lead
to increased IL-1 production and increased tissue destruc-
tion.36 This cytokine, by suppressing the innate and protective
adaptive immune responses, is also involved in the persis-
tence of bacteria and in the maintenance of chronic infec-
tions.36 In addition, microbiological studies have
demonstrated similar proportions of presumptive pathogens,
both around implants and in periodontal disease, therefore, it
is reasonable to hypothesize that IL-10 acts similarly in both
periodontitis and in implant failure.47,48
A previous study evaluating pro/anti-inflammatory cyto-
kine mRNA levels in peri-implant tissue from patients with
Branemark titanium implants showed that gingival mucosa
from pre-surgery edentulous patients preferentially expressedes) in studied groups.
nt failure
 (%)
p OR 95% CI
0.91 0.92 0.50–1.69
0.57 0.67 0.25–1.77
0.67 0.82 0.42–1.58
0.55 1.36 0.62–2.99
0.86 1.32 0.21–8.08
0.77 1.19 0.57–2.51
0.88 1.11 0.55–2.23
0.86 2.00 0.24–14.4
y y y
y y y
ervals.
oups.
nt failure
 (%)
p OR 95% CI
.3) 0.94 1.00 0.68–1.47
.3) 0.49 1.16 0.79–1.72
.1) 0.46 0.83 0.55–1.26
1) 0.67 0.98 0.17–5.44
1) 0.86 1.98 0.27–14.2
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10 expression increased strongly at 4 months, decreased at 8
months, and became almost undetectable at 12 months
suggesting that these cytokines combine to regulate immu-
noinflammatory balance in periimplant mucosa.49 Higher
concentration of IL-10 was also found in individuals with
periimplantitis.50 In contrast, Duarte et al.51 observed no
differences in the IL-10 levels between patients with periim-
plantitis and healthy subjects. Moreover, Duarte et al.51 also
showed that IL-10 was not modulated by the periimplant
antiinfective therapy 3 months after the therapy.
Allelic variation in cytokine genes and factors regulating
their expressions result in phenotypic differences in cytokine
responses among individuals, which may be important in
susceptibility and progression52 of diseases such as periodon-
tal disease53 and dental implants failure.10 The most com-
monly studied functional polymorphisms for dental implant
failure are variations of the IL-1 gene cluster, but no
association evidence was found between IL1A and IL1B gene
polymorphisms and implant failure.54 Otherwise, in a partially
edentulous group treated for periodontal disease prior to
implant treatment, a synergistic effect between the IL1
positive genotype and smoking was detected.55 In addition,
the genotype 2/2 of IL1RN polymorphism was significantly
more frequent in individuals with multiple implant losses in a
Brazilian population,11 the same investigated in the present
study.
Other genetic markers for dental implant failure have been
investigated in the last years. In the promoter region of the
metalloproteinase-1 (MMP-1) gene, the 2G polymorphism was
associated with early implant failure in nonsmokers in a
Brazilian population.12 Nevertheless, MMP-912, IL2, IL656,
TNFA,57 and TNFB112 gene polymorphisms were not useful
predictors of the pathologic or clinical consequences of
osseointegration.
It can be noted that the genes chosen for investigating
the genetic influence in dental implant loss are those
previously investigated as candidate genes for periodontal
disease. Studies focusing the association of IL10 gene
polymorphisms and periodontal disease show contradictory
results. Two previous studies have failed to show associa-
tion between IL10 gene polymorphisms and periodontal
disease.37,58,59 Scarel-Caminaga et al.37 analysed the same
three polymorphisms in the IL10 gene and observed that the
819 and 592 SNPs were associated with susceptibility to
the chronic periodontitis in a population similar to the
investigated in the present study. Individuals with the CT
and TT genotypes for the 819 SNP demonstrated the
OR = 3.04 (95% CI = 1.34–6.91) and those carrying the CA and
AA genotypes for the 592 SNP showed the OR = 2.41 (95%
CI = 1.084–5.36). In accordance, Claudino et al.35, verified
that IL-10-592 CA, AA and CA+AA genotypes were found to
be more frequent in patients with chronic periodontal
disease than in the controls. Also, they found that the
carriers of CA and AA genotypes of 592 SNP showed a
significantly lower expression of IL-10 mRNA in periodontal
tissues than those with the CC genotype.35
Because of the IL-10 induces the expression of tissue
inhibitors of metalloproteinases (TIMPs) and the inhibitor of
osteoclastogenesis, osteoprotegerin (OPG), the respectiveinhibitors of MMPs and RANKL systems, IL-10 is thought to
attenuate periodontal disease severity.60 Interestingly, car-
riers of CA and AA genotypes of the 592 IL10 SNP express
significant lower levels of TIMPs and OPG in diseased
periodontal tissues when compared with CC genotype
patients. Therefore, the 592 SNP in the IL10 gene was
associated with low levels of IL-10 mRNA expression, which
was supposed to consequently decrease the expression of the
downstream genes TIMP and OPG and influence periodontal
disease outcome.35 In spite of these interesting results, the
592 and the 1082 SNPs in the IL10 gene were not associated
with the failure of dental implant osseointegration. Regarding
the 819(C/T) genotype and rheumatism and cardiovascular
diseases, the present study demonstrated positive association
with dental implant loss, but considering the p value corrected
for multiple comparisons these results lost their significance.
The only covariate significantly different between cases and
controls was the smoking habits ( p = 0.0001), but in the
multivariate analysis it lost that statistical difference
( p = 0.6829).
When a genetic analysis includes a haplotype, the
cooperative influence of different polymorphisms in linkage
disequilibrium is considered instead of one polymorphism
individually, and then the potential influence of the genetic
factor is more confident.61 Scarel-Caminaga37 showed that
women carrying the ATA haplotype in the IL10 gene seemed to
be 2.5 times more likely to develop chronic periodontitis than
those carrying the ACC haplotype. Previously, the ATA
haplotype influenced lower transcriptional activity of IL10
than the GCC haplotype.38 Therefore, individuals in the
diseased group with ATA haplotype would have lower levels
of IL-10, which could explain the excess of inflammatory
cytokines present in periodontal lesions of the chronic form of
the disease.38 However, another study found that individuals
with ATA/ACC or ACC/ACC genotypes had less disease
progression than those with other genotypes.36
Association studies of different diseases have investigated
the same IL10 haplotypes with interesting results.29,33,62,63 The
haplotype ACC/ACC, associated with low production of IL-10
in patients with endometriosis, was significantly more
frequent in those patients than in healthy controls.63 Patients
carrying the ATA haplotype with peripheral arterial disease
showed a high risk of cardiovascular events (relative
risk = 2.16, 95% confidence interval = 1.41–5.11) in comparison
with those carrying all the GCC, GCA, GTA, GTC haplotypes.62
Interestingly, in the present study, our large sample data
presented a major frequency of GCA haplotype in both groups.
Recently, this GCA haplotype was mentioned as associated
with production of high serum levels of IL-10, which is
protective against atherogenesis.62
In conclusion, with the aim of contributing to the
knowledge of the possible influence of the host genetic
carriage for dental implant losses, the present study demon-
strated no association of either IL10 gene polymorphisms,
haplotypes and other covariates with susceptibility to dental
implant failure in the studied population. Further studies in
other populations presenting similar clinical conditions might
contribute with well understanding the potential influence of
genetic and other host variables in the dental implant
osseointegration failure.
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